Palbociclib expanded access program now open to eligible U.S. patients with HR+, HER2
Pfizer Inc. has announced that the company has initiated a multi-center, open-label expanded access program (EAP) in the United States for the investigational CDK 4/6 inhibitor, palbociclib.